Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

rebecsinib

Phase 1Small molecule

AAspera Biomedicines, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Secondary AMLRecruiting

Secondary AMLPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Secondary AML

NCT07250646

Clinical

Trials by Indication[1]

Secondary AML1 trial

A Phase 1 Study of Rebecsinib, a Spliceosome Modulator That Inhibits ADAR1, in Patients With Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis

Recruiting·AAspera Biomedicines, Inc.·Phase 1·NCT07250646·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for rebecsinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rebecsinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rebecsinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aspera Biomedicines, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAspera Biomedicines, Inc.

Related News